| 2026-08-13 | Press release | Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-07-21 | Press release | Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In |
| 2026-07-15 | Press release | Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 |
| 2026-06-04 | Press release | Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors |
| 2026-05-29 | Press release | Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds |
| 2026-05-14 | Press release | Tempest Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-06 | Press release | Tempest Presents Clinical Update at ISCT 2026 Annual Meeting |
| 2026-04-29 | Press release | Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting |
| 2026-04-22 | Press release | Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T |
| 2026-04-14 | Press release | Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licens |
| Press release | Tempest Reports Year End 2025 Financial Results and Provides Business Update |
| Press release | Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 |
| Quarterly report | Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational |
| Press release | Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets |
| Press release | Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets |
| Press release | Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projec |
| Press release | Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China |
| Press release | Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients |
| Press release | Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meet |
| Press release | Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP |
| Press release | Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and M |
| Press release | Tempest Reports Year End 2024 Financial Results and Provides Business Update |
| Presentation | Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeti |
| Press release | FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis |
| Press release | Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with H |
| Press release | Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with |
| Press release | Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference |
| Press release | Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of F |
| Press release | Tempest Extends Limited Duration Stockholder Rights Plan |
| Press release | Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocel |
| Press release | Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs |
| Press release | Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
| Press release | Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance |
| Press release | Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellula |
| Press release | Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month |
| Press release | Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellula |
| Press release | Tempest to Participate in Upcoming Investor Conferences |
| Press release | Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in |
| Press release | Tempest Reports Year End 2023 Financial Results and Provides Business Update |
| Press release | Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 |